Bivalirudin vs Insulin
Overview
Bivalirudin is primarily a cardiovascular peptide, while Insulin is used for weight management & metabolic.
This page compares Bivalirudin and Insulin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bivalirudin | Insulin | |
|---|---|---|
| Category | Cardiovascular | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion | Highly individualized; type 1 diabetes basal-bolus regimens typically require 0.5–1.0 units/kg/day total; type 2 diabetes is often initiated with basal insulin at 10 units or 0.1–0.2 units/kg/day, titrated to individual glycemic targets |
| Frequency | Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours | Once daily (long-acting basal analogs) to four or more times daily (basal-bolus or continuous subcutaneous insulin infusion); prandial doses given 0–15 minutes before meals for rapid-acting analogs or 30 minutes before meals for regular human insulin |
| Reported benefits | Anticoagulation during PCI and PTCA, anticoagulation in HIT/HITTS patients undergoing PCI, reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor, predictable pharmacokinetics without need for antithrombin cofactor, rapid offset of anticoagulation due to short half-life, inhibition of both circulating and clot-bound thrombin | Glycemic control, prevention of diabetic ketoacidosis, reduction of microvascular complications (retinopathy, nephropathy, neuropathy), life-sustaining therapy in type 1 diabetes, HbA1c reduction in type 2 diabetes |
| Reported side effects | Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare) | Hypoglycemia, weight gain, injection-site lipohypertrophy, rare hypersensitivity reactions, peripheral edema at initiation |
Key differences
Primary use. Bivalirudin is categorised under Cardiovascular, while Insulin falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bivalirudin: FDA-approved. Insulin: FDA-approved.
Dosing. Bivalirudin is typically dosed at 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours). Insulin is typically dosed at Highly individualized; type 1 diabetes basal-bolus regimens typically require 0.5–1.0 units/kg/day total; type 2 diabetes is often initiated with basal insulin at 10 units or 0.1–0.2 units/kg/day, titrated to individual glycemic targets (Once daily (long-acting basal analogs) to four or more times daily (basal-bolus or continuous subcutaneous insulin infusion); prandial doses given 0–15 minutes before meals for rapid-acting analogs or 30 minutes before meals for regular human insulin).
Can you stack them?
Some protocols combine peptides, but stacking Bivalirudin and Insulin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bivalirudin and Insulin?
- Bivalirudin is primarily a cardiovascular peptide, while Insulin is used for weight management & metabolic. Bivalirudin is FDA-approved for one or more indications, whereas Insulin is FDA-approved for one or more indications.
- What is Bivalirudin used for?
- FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.
- What is Insulin used for?
- The foundational peptide hormone for glycemic management in type 1 and type 2 diabetes mellitus.
- Can you take Bivalirudin and Insulin together?
- Some users combine peptides within a single protocol, but stacking Bivalirudin and Insulin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bivalirudin or Insulin FDA-approved?
- Bivalirudin is FDA-approved for one or more indications. Insulin is FDA-approved for one or more indications.
Read the full articles
- Bivalirudin — full monograph: mechanism, research, dosing & references
- Insulin — full monograph: mechanism, research, dosing & references